对阿波罗内外科公司（纳斯达克股票代码：APEN）的空头兴趣增长了29.4％

Apollo Endosurgery, Inc. (NASDAQ:APEN – Get Rating) saw a large growth in short interest during the month of December. As of December 30th, there was short interest totalling 550,900 shares, a growth of 29.4% from the December 15th total of 425,700 shares. Based on an average daily volume of 870,400 shares, the days-to-cover ratio is currently 0.6 days.

Apollo Endosurgery Price Performance

Apollo Endosurgery stock opened at $9.84 on Friday. The company's 50 day simple moving average is $9.10 and its 200 day simple moving average is $6.90. Apollo Endosurgery has a fifty-two week low of $3.49 and a fifty-two week high of $10.30. The firm has a market capitalization of $467.88 million, a price-to-earnings ratio of -9.65 and a beta of 2.35. The company has a debt-to-equity ratio of 1.26, a current ratio of 6.00 and a quick ratio of 4.98.

Get Apollo Endosurgery alerts:

Apollo Endosurgery (NASDAQ:APEN – Get Rating) last announced its earnings results on Tuesday, November 1st. The biotechnology company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.07). The company had revenue of $19.57 million for the quarter, compared to analyst estimates of $17.97 million. Apollo Endosurgery had a negative return on equity of 78.73% and a negative net margin of 56.74%. As a group, sell-side analysts anticipate that Apollo Endosurgery will post -0.97 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Stifel Nicolaus lowered shares of Apollo Endosurgery from a "buy" rating to a "hold" rating and set a $10.00 target price on the stock. in a research note on Tuesday, January 3rd. Lake Street Capital lowered shares of Apollo Endosurgery from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $14.00 to $10.00 in a research note on Wednesday, November 30th.

Institutional Trading of Apollo Endosurgery

Hedge funds have recently bought and sold shares of the stock. Silverarc Capital Management LLC raised its holdings in Apollo Endosurgery by 7.0% during the 2nd quarter. Silverarc Capital Management LLC now owns 1,074,879 shares of the biotechnology company's stock worth $3,923,000 after buying an additional 70,480 shares during the period. Morris Financial Concepts Inc. acquired a new stake in shares of Apollo Endosurgery in the second quarter valued at approximately $41,000. Lazard Asset Management LLC raised its holdings in shares of Apollo Endosurgery by 77.5% in the second quarter. Lazard Asset Management LLC now owns 10,904 shares of the biotechnology company's stock valued at $39,000 after purchasing an additional 4,762 shares during the last quarter. Walleye Capital LLC acquired a new stake in shares of Apollo Endosurgery in the second quarter valued at approximately $44,000. Finally, Jump Financial LLC acquired a new stake in shares of Apollo Endosurgery in the third quarter valued at approximately $62,000. 76.01% of the stock is currently owned by institutional investors and hedge funds.

About Apollo Endosurgery

(Get Rating)

Apollo Endosurgery, Inc is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, the OverStitch Sx Endoscopic Suturing System, and the Orbera Intragastric Balloon System.

Read More

• Get a free copy of the StockNews.com research report on Apollo Endosurgery (APEN)
• MarketBeat Week in Review – 1/16 – 1/20
• Does Old Dominion Show That Trucking Is Hitting The Brakes?
• Nordstrom Puts Fear Of Markdowns Into Retail Sector
• Exxon Mobil Stock: Within Striking Distance Of Buy Point
• High-Dividend-Yielding BHP Sees China Driving '23 Growth

Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.